Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin

Open access

Abstract

Physical activity provides clinical benefit in Parkinson’s disease (PD). Irisin is an exercise-induced polypeptide secreted by skeletal muscle that crosses the blood–brain barrier and mediates certain effects of exercise. Here, we show that irisin prevents pathologic α-synuclein (α-syn)-induced neurodegeneration in the α-syn preformed fibril (PFF) mouse model of sporadic PD. Intravenous delivery of irisin via viral vectors following the stereotaxic intrastriatal injection of α-syn PFF cause a reduction in the formation of pathologic α-syn and prevented the loss of dopamine neurons and lowering of striatal dopamine. Irisin also substantially reduced the α-syn PFF-induced motor deficits as assessed behaviorally by the pole and grip strength test. Recombinant sustained irisin treatment of primary cortical neurons attenuated α-syn PFF toxicity by reducing the formation of phosphorylated serine 129 of α-syn and neuronal cell death. Tandem mass spectrometry and biochemical analysis revealed that irisin reduced pathologic α-syn by enhancing endolysosomal degradation of pathologic α-syn. Our findings highlight the potential for therapeutic disease modification of irisin in PD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2204835119

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. Irisin protects neurons against α-syn PFF neurotoxicity. (A) Representative images of pS129-α-syn (green) in primary cortical neurons preincubated for 1 h followed by sustained treatment with indicated concentration of irisin, and further incubated with α-syn PFF (1 μg/mL) for 7 d. DAPI (blue) was used for nuclei staining. (Scale bar, 20 μm.) (B) Quantification of p-α-syn signals in (A) normalized with DAPI. Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 3). (C) Representative immunoblots of pS129-α-syn and α-syn in the Triton X-100-soluble and insoluble fraction from primary cortical neurons preincubated for 1 h followed by sustained treatment with indicated concentration of irisin followed by incubation with α-syn PFF for 7 d. (D) Quantification of levels of pS129-α-syn and α-syn in the Triton X-100-insoluble fraction normalized to β-actin shown in (C). Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 4). (E) Cell death assay quantified from Hoechst and propidium iodide (PI) staining in primary cortical neurons treated for 1 h followed by sustained treatment with indicated concentration of irisin and further incubated with α-syn PFF (5 μg/mL) for 14 d. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 4). (F) Cell death assay quantified from Hoechst and propidium iodide (PI) staining in primary cortical neurons preincubated 1 h followed by sustained treatment with irisin (50 ng/mL) and further incubated with α-syn PFF (5 μg/mL) for 14 d as well as delayed treatment (1 d, 2 d, 4 d, and 7 d) after α-syn PFF treatment. Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 4). *P < 0.05, **P < 0.005, ***P < 0.0005.
Fig. 1. Irisin protects neurons against α-syn PFF neurotoxicity. (A) Representative images of pS129-α-syn (green) in primary cortical neurons preincubated for 1 h followed by sustained treatment with indicated concentration of irisin, and further incubated with α-syn PFF (1 μg/mL) for 7 d. DAPI (blue) was used for nuclei staining. (Scale bar, 20 μm.) (B) Quantification of p-α-syn signals in (A) normalized with DAPI. Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 3). (C) Representative immunoblots of pS129-α-syn and α-syn in the Triton X-100-soluble and insoluble fraction from primary cortical neurons preincubated for 1 h followed by sustained treatment with indicated concentration of irisin followed by incubation with α-syn PFF for 7 d. (D) Quantification of levels of pS129-α-syn and α-syn in the Triton X-100-insoluble fraction normalized to β-actin shown in (C). Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 4). (E) Cell death assay quantified from Hoechst and propidium iodide (PI) staining in primary cortical neurons treated for 1 h followed by sustained treatment with indicated concentration of irisin and further incubated with α-syn PFF (5 μg/mL) for 14 d. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 4). (F) Cell death assay quantified from Hoechst and propidium iodide (PI) staining in primary cortical neurons preincubated 1 h followed by sustained treatment with irisin (50 ng/mL) and further incubated with α-syn PFF (5 μg/mL) for 14 d as well as delayed treatment (1 d, 2 d, 4 d, and 7 d) after α-syn PFF treatment. Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 4). *P < 0.05, **P < 0.005, ***P < 0.0005.CC BY · PubMed Central
Fig. 2. Irisin protects α-syn PFF-induced pathology in vivo. (A) Diagram of in vivo experiments. Two-month-old WT mice were injected with PBS or α-syn PFF (5 μg/mouse) into the striatum. Two weeks after α-syn PFF injection, the mice were injected with AAV8-GFP or AAV8-Irisin-FLAG (1E10 G.C./mouse) via the tail vein. The mice were subjected to behavioral test (pole test and grip strength test), stereology and biochemical analysis 6 mo after α-syn PFF injection. (B) Representative TH and Nissl staining of SNpc DA neurons of PBS or α-syn PFF injected mice treated with AAV-GFP or AAV-Irisin. (Scale bars, 400 μm.) (C, D) Stereological counts of (C) TH+ and (D) TH+/Nissl+ cells. Data are mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 5 mice per group). i = ipsilateral, c = contralateral. (E) Representative immunoblots and quantification of TH and DAT in the ipsilateral striatum of injected mice. Bars represent the mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 4). (F) DA concentrations in the striatum of PBS or α-syn PFF injected mice treated with AAV-GFP or AAV-Irisin determined by HPLC. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test. (n = 7 mice per group). (G) Representative immunoblots of pS129-α-syn and α-syn in the detergent-soluble and insoluble fraction from the SNpc of injected mice. (H) Quantification of pS129-α-syn and α-syn levels in the detergent-insoluble fraction normalized to β-actin. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 3). (I, J) Pole test (I) and grip strength (J) test were performed 6 mo after PBS or α-syn PFF injection. Data are the mean ± SEM *P < 0.05, ***P < 0.0005, two-way ANOVA followed by Tukey’s post hoc test (n = 12–13 mice per group). *P < 0.05, **P < 0.005, ***P < 0.0005.
Fig. 2. Irisin protects α-syn PFF-induced pathology in vivo. (A) Diagram of in vivo experiments. Two-month-old WT mice were injected with PBS or α-syn PFF (5 μg/mouse) into the striatum. Two weeks after α-syn PFF injection, the mice were injected with AAV8-GFP or AAV8-Irisin-FLAG (1E10 G.C./mouse) via the tail vein. The mice were subjected to behavioral test (pole test and grip strength test), stereology and biochemical analysis 6 mo after α-syn PFF injection. (B) Representative TH and Nissl staining of SNpc DA neurons of PBS or α-syn PFF injected mice treated with AAV-GFP or AAV-Irisin. (Scale bars, 400 μm.) (C, D) Stereological counts of (C) TH+ and (D) TH+/Nissl+ cells. Data are mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 5 mice per group). i = ipsilateral, c = contralateral. (E) Representative immunoblots and quantification of TH and DAT in the ipsilateral striatum of injected mice. Bars represent the mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 4). (F) DA concentrations in the striatum of PBS or α-syn PFF injected mice treated with AAV-GFP or AAV-Irisin determined by HPLC. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test. (n = 7 mice per group). (G) Representative immunoblots of pS129-α-syn and α-syn in the detergent-soluble and insoluble fraction from the SNpc of injected mice. (H) Quantification of pS129-α-syn and α-syn levels in the detergent-insoluble fraction normalized to β-actin. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 3). (I, J) Pole test (I) and grip strength (J) test were performed 6 mo after PBS or α-syn PFF injection. Data are the mean ± SEM *P < 0.05, ***P < 0.0005, two-way ANOVA followed by Tukey’s post hoc test (n = 12–13 mice per group). *P < 0.05, **P < 0.005, ***P < 0.0005.CC BY · PubMed Central
Fig. 3. Irisin reduces the α-syn levels. (A) Schematic diagram of proteomic analysis. (B, C) Volcano plot of protein alterations. The proteins quantified from primary cortical neurons with or without preincubation of irisin (50 ng/mL) and further incubated with α-syn PFF (1 μg/mL) for (B) one or (C) 4 d were analyzed for differentially expressed proteins in PFF- and irisin-treated cells. The cutoff used to select differentially expressed proteins was q-value < 0.05. (D, E) Relative protein levels of (D) ApoE and (E) Snca in primary cortical neurons 1 and 4 d after PBS, α-syn PFF, or α-syn PFF with irisin administration analyzed by mass spec. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 3). (F) Representative immunoblots of pS129-α-syn, α-syn and α-syn-biotin in the detergent- insoluble and soluble fraction from cortical neurons 1 and 4 d after treatment. (G) Quantification of α-syn-biotin and α-syn levels in the detergent-soluble fraction normalized to β-actin. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 3). *P < 0.05, **P < 0.005, ***P < 0.0005. ND, not determined; ns, not significant.
Fig. 3. Irisin reduces the α-syn levels. (A) Schematic diagram of proteomic analysis. (B, C) Volcano plot of protein alterations. The proteins quantified from primary cortical neurons with or without preincubation of irisin (50 ng/mL) and further incubated with α-syn PFF (1 μg/mL) for (B) one or (C) 4 d were analyzed for differentially expressed proteins in PFF- and irisin-treated cells. The cutoff used to select differentially expressed proteins was q-value < 0.05. (D, E) Relative protein levels of (D) ApoE and (E) Snca in primary cortical neurons 1 and 4 d after PBS, α-syn PFF, or α-syn PFF with irisin administration analyzed by mass spec. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 3). (F) Representative immunoblots of pS129-α-syn, α-syn and α-syn-biotin in the detergent- insoluble and soluble fraction from cortical neurons 1 and 4 d after treatment. (G) Quantification of α-syn-biotin and α-syn levels in the detergent-soluble fraction normalized to β-actin. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 3). *P < 0.05, **P < 0.005, ***P < 0.0005. ND, not determined; ns, not significant.CC BY · PubMed Central
Fig. 4. Irisin increases the degradation of pathologic α-syn. (A, B) Primary cortical neurons from WT embryos were pretreated with 50 ng/mL Irisin for 1 h and further incubated with biotin-conjugated α-syn PFF (1 μg/mL) for 24 h. The levels of α-syn-biotin and α-syn in the endolysosome-enriched fraction were determined by immunoblotting using anti-streptavidin and an anti-α-syn antibody, respectively. Rab7 is a marker for endosome, Lamp2 is a marker for lysosome, HSP60 is a marker for mitochondria, and α-tubulin is a marker for cytoplasm. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 4). (C) Irisin promotes intracellular degradation of propagated α-syn PFF. Primary cortical neurons were pretreated with 50 ng/mL Irisin for 1 h and further incubated with biotin-conjugated α-syn PFF (1 μg/mL) in the presence of 50 ng/mL irisin for 12 h followed by media replacement with 50 ng/mL irisin not containing α-syn PFF. Intracellular biotin-conjugated α-syn PFF levels were determined by immunoblotting using anti-streptavidin antibody 3, 6, and 12 h after changing to fresh medium containing 50 ng/mL irisin. Graph represents mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 3). (D, E) Propagated α-syn PFF is degraded by the lysosome. Primary cortical neurons were pretreated with 50 ng/mL Irisin for 1 h and further incubated with biotin-conjugated α-syn PFF (1 μg/mL) for 12 h, followed by the fresh medium or medium containing NH4Cl was replaced for 3 h. The levels of α-syn-biotin and α-syn were determined by immunoblotting using anti-streptavidin and α-syn antibodies, respectively. Graph represents mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 3). (F) Representative microscopic images of pS129-α-syn (green) in primary cortical neurons treated with α-syn PFF (1 μg/mL) for 4 d. Two days after α-syn PFF treatment, irisin and NH4Cl were incubated for 2 d. DAPI (blue) is used for nuclei staining. (Scale bar, 20 μm.) Quantification of p-α-syn signals was normalized with DAPI. Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 3). (G) Representative immunoblots of pS129-α-syn and α-syn in the detergent-soluble and insoluble fraction from primary cortical neurons incubated with α-syn PFF for 4 d followed by posttreated with irisin and NH4Cl for 2 d. (H) Quantification of pS129-α-syn and α-syn levels in the detergent-insoluble fraction normalized to β-actin. Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 4). *P < 0.05, **P < 0.005, ***P < 0.0005. ND, not determined; ns, not significant.
Fig. 4. Irisin increases the degradation of pathologic α-syn. (A, B) Primary cortical neurons from WT embryos were pretreated with 50 ng/mL Irisin for 1 h and further incubated with biotin-conjugated α-syn PFF (1 μg/mL) for 24 h. The levels of α-syn-biotin and α-syn in the endolysosome-enriched fraction were determined by immunoblotting using anti-streptavidin and an anti-α-syn antibody, respectively. Rab7 is a marker for endosome, Lamp2 is a marker for lysosome, HSP60 is a marker for mitochondria, and α-tubulin is a marker for cytoplasm. Bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 4). (C) Irisin promotes intracellular degradation of propagated α-syn PFF. Primary cortical neurons were pretreated with 50 ng/mL Irisin for 1 h and further incubated with biotin-conjugated α-syn PFF (1 μg/mL) in the presence of 50 ng/mL irisin for 12 h followed by media replacement with 50 ng/mL irisin not containing α-syn PFF. Intracellular biotin-conjugated α-syn PFF levels were determined by immunoblotting using anti-streptavidin antibody 3, 6, and 12 h after changing to fresh medium containing 50 ng/mL irisin. Graph represents mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 3). (D, E) Propagated α-syn PFF is degraded by the lysosome. Primary cortical neurons were pretreated with 50 ng/mL Irisin for 1 h and further incubated with biotin-conjugated α-syn PFF (1 μg/mL) for 12 h, followed by the fresh medium or medium containing NH4Cl was replaced for 3 h. The levels of α-syn-biotin and α-syn were determined by immunoblotting using anti-streptavidin and α-syn antibodies, respectively. Graph represents mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test (n = 3). (F) Representative microscopic images of pS129-α-syn (green) in primary cortical neurons treated with α-syn PFF (1 μg/mL) for 4 d. Two days after α-syn PFF treatment, irisin and NH4Cl were incubated for 2 d. DAPI (blue) is used for nuclei staining. (Scale bar, 20 μm.) Quantification of p-α-syn signals was normalized with DAPI. Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 3). (G) Representative immunoblots of pS129-α-syn and α-syn in the detergent-soluble and insoluble fraction from primary cortical neurons incubated with α-syn PFF for 4 d followed by posttreated with irisin and NH4Cl for 2 d. (H) Quantification of pS129-α-syn and α-syn levels in the detergent-insoluble fraction normalized to β-actin. Bars represent mean ± SEM. One-way ANOVA followed by Tukey’s post hoc test (n = 4). *P < 0.05, **P < 0.005, ***P < 0.0005. ND, not determined; ns, not significant.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Cited by

See all 125

Metadata

Authors
Kam, T.-I., Park, H., Chou, S.-C., Van Vranken, J. G., Mittenbühler, M. J., Kim, H., A, M., Choi, Y. R., Biswas, D., Wang, J., Shin, Y., Loder, A., Karuppagounder, S. S., Wrann, C. D., Dawson, V. L., Spiegelman, B. M., & Dawson, T. M.
Affiliations
  • Johns Hopkins University (US)
  • Department of Cell Biology, Harvard Medical School, Boston, MA, 02215
  • Harvard University (US)
Corresponding author
  • Spiegelman, Bruce M.
  • Dawson, Ted M.
Venue
Proceedings of the National Academy of Sciences
Published
2022-08-31
Volume
119
Issue
36
Pages
e2204835119-e2204835119
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4293785272
Cited by
125
References
51
Citations by year
2026: 25 · 2025: 38 · 2024: 39 · 2023: 20 · 2022: 3
FWCI
13.16
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • JPB Foundation (N/A)
  • Maryland Stem Cell Research Fund (2020-MSCRFL-5427)
  • Damon Runyon Cancer Research Foundation (DRG 2359-19)
  • Deutsche Forschungsgemeinschaft (461079553)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
irisin, Parkinson's disease, alpha-synuclein, preformed fibrils, neurodegeneration, dopaminergic neurons, striatum, motor impairment, serine 129 phosphorylation, endolysosomal degradation, viral gene delivery, physical activity
MeSH terms
Animals, Corpus Striatum, Disease Models, Animal, Fibronectins, Parkinson Disease, Mice, alpha-Synuclein, Dopaminergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin. https://app.cochat.ai/papers/10.1073/pnas.2204835119
The paper
Kam, T.-I., Park, H., Chou, S.-C., Van Vranken, J. G., Mittenbühler, M. J., Kim, H., A, M., Choi, Y. R., Biswas, D., Wang, J., Shin, Y., Loder, A., Karuppagounder, S. S., Wrann, C. D., Dawson, V. L., Spiegelman, B. M., & Dawson, T. M. (2022). Amelioration of pathologic α-synuclein-induced Parkinson’s disease by irisin. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2204835119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.